Jaguar health to present october 17 at the lytham partners fall 2023 investor conference and october 18 at the bio investor forum

Top line results expected in the coming weeks for company's phase 3 ontarget trial of crofelemer for preventative treatment of cancer therapy-related diarrhea jaguar is supporting investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of short bowel syndrome and microvillus inclusion disease in the us, eu, and middle east/north africa regions, with results expected before the end of 2023 and in 2024 san francisco, ca / accesswire / october 12, 2023 / jaguar health, inc. (nasdaq:jagx) today announced that lisa conte, the company's founder, president and ceo, will present and host one-on-one meetings with investors during the lytham partners fall 2023 investor conference, taking place virtually on october 17, 2023, and on october 18, 2023 at the in-person bio investor forum. participation instructions for jaguar health presentation at the lytham partners fall 2023 investor conference company webcast: jaguar health's webcast presentation will be available for viewing at 7:00 am eastern on tuesday, october 17, 2023, at https://wsw.com/webcast/lytham9/jagx/2033040.
JAGX Ratings Summary
Quant
JAGX Quant Ranking
Sector
Industry
Quant Rating
Quant Score